These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Itch associated with skin disease: advances in pathophysiology and emerging therapies. Yosipovitch G; Fleischer A Am J Clin Dermatol; 2003; 4(9):617-22. PubMed ID: 12926980 [TBL] [Abstract][Full Text] [Related]
5. Breaking the Itch-Scratch Cycle: Topical Options for the Management of Chronic Cutaneous Itch in Atopic Dermatitis. Harrison IP; Spada F Medicines (Basel); 2019 Jul; 6(3):. PubMed ID: 31323753 [TBL] [Abstract][Full Text] [Related]
6. Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus. Morgenweck J; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM Neuropharmacology; 2015 Dec; 99():600-9. PubMed ID: 26318102 [TBL] [Abstract][Full Text] [Related]
8. Chronic pruritus: targets, mechanisms and future therapies. Pogatzki-Zahn E; Marziniak M; Schneider G; Luger TA; Ständer S Drug News Perspect; 2008 Dec; 21(10):541-51. PubMed ID: 19221635 [TBL] [Abstract][Full Text] [Related]
9. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Soeberdt M; Kilic A; Abels C Eur J Pharmacol; 2020 Aug; 881():173242. PubMed ID: 32504692 [TBL] [Abstract][Full Text] [Related]
10. Atopic itch in dogs: pharmacology and modeling. Olivry T; Bäumer W Handb Exp Pharmacol; 2015; 226():357-69. PubMed ID: 25861789 [TBL] [Abstract][Full Text] [Related]
11. Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications. Elmariah S; Chisolm S; Sciascia T; Kwatra SG JAAD Int; 2022 Jun; 7():156-163. PubMed ID: 35497636 [TBL] [Abstract][Full Text] [Related]
12. Sex differences in the pharmacology of itch therapies-a narrative review. Schmid Y; Navarini A; Thomas ZM; Pfleiderer B; Krähenbühl S; Mueller SM Curr Opin Pharmacol; 2019 Jun; 46():122-142. PubMed ID: 31299512 [TBL] [Abstract][Full Text] [Related]
13. Anti pruritic effects of topical crotamiton, capsaicin, and a corticosteroid on pruritogen-induced scratching behavior. Sekine R; Satoh T; Takaoka A; Saeki K; Yokozeki H Exp Dermatol; 2012 Mar; 21(3):201-4. PubMed ID: 22379965 [TBL] [Abstract][Full Text] [Related]
14. Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans. Inan S; Cowan A Handb Exp Pharmacol; 2022; 271():275-292. PubMed ID: 33296031 [TBL] [Abstract][Full Text] [Related]
15. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus. Ständer S; Yosipovitch G Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733 [TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of pruritus. Meng J; Steinhoff M Curr Res Transl Med; 2016; 64(4):203-206. PubMed ID: 27939459 [TBL] [Abstract][Full Text] [Related]
17. Renal itch. Murphy M; Carmichael AJ Clin Exp Dermatol; 2000 Mar; 25(2):103-6. PubMed ID: 10733630 [TBL] [Abstract][Full Text] [Related]
18. Itch Management in the Elderly. Leslie TA Curr Probl Dermatol; 2016; 50():192-201. PubMed ID: 27578088 [TBL] [Abstract][Full Text] [Related]